| pubmed-article:7905523 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7905523 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:7905523 | lifeskim:mentions | umls-concept:C0043474 | lld:lifeskim |
| pubmed-article:7905523 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:7905523 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:7905523 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:7905523 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:7905523 | lifeskim:mentions | umls-concept:C1332714 | lld:lifeskim |
| pubmed-article:7905523 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:7905523 | lifeskim:mentions | umls-concept:C1300557 | lld:lifeskim |
| pubmed-article:7905523 | lifeskim:mentions | umls-concept:C0074118 | lld:lifeskim |
| pubmed-article:7905523 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7905523 | pubmed:dateCreated | 1994-3-4 | lld:pubmed |
| pubmed-article:7905523 | pubmed:abstractText | We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone. Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo. Sixty patients received combination therapy and 58, zidovudine and placebo. Twenty-three patients (38%) and 15 (26%), in the combination and zidovudine groups, respectively, discontinued therapy (p = 0.15). The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV). The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36). For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively. The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:7905523 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7905523 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7905523 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7905523 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7905523 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7905523 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7905523 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7905523 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7905523 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7905523 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7905523 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7905523 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7905523 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:7905523 | pubmed:issn | 0894-9255 | lld:pubmed |
| pubmed-article:7905523 | pubmed:author | pubmed-author:FassR JRJ | lld:pubmed |
| pubmed-article:7905523 | pubmed:author | pubmed-author:AspinallR LRL | lld:pubmed |
| pubmed-article:7905523 | pubmed:author | pubmed-author:FifeK HKH | lld:pubmed |
| pubmed-article:7905523 | pubmed:author | pubmed-author:ResnickLL | lld:pubmed |
| pubmed-article:7905523 | pubmed:author | pubmed-author:CollierA CAC | lld:pubmed |
| pubmed-article:7905523 | pubmed:author | pubmed-author:PowderlyW GWG | lld:pubmed |
| pubmed-article:7905523 | pubmed:author | pubmed-author:FischlM AMA | lld:pubmed |
| pubmed-article:7905523 | pubmed:author | pubmed-author:KremerA BAB | lld:pubmed |
| pubmed-article:7905523 | pubmed:author | pubmed-author:PottageJ... | lld:pubmed |
| pubmed-article:7905523 | pubmed:author | pubmed-author:CoombsRR | lld:pubmed |
| pubmed-article:7905523 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7905523 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:7905523 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7905523 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:7905523 | pubmed:pagination | 139-47 | lld:pubmed |
| pubmed-article:7905523 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:meshHeading | pubmed-meshheading:7905523-... | lld:pubmed |
| pubmed-article:7905523 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7905523 | pubmed:articleTitle | The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. | lld:pubmed |
| pubmed-article:7905523 | pubmed:affiliation | University of Miami School of Medicine, Florida. | lld:pubmed |
| pubmed-article:7905523 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7905523 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7905523 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:7905523 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:7905523 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7905523 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7905523 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7905523 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7905523 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7905523 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7905523 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7905523 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7905523 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7905523 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7905523 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7905523 | lld:pubmed |
